OCEANSIX-FUTURE-PATHS-LT
15.5.2024 12:49:30 CEST | Business Wire | Press release
oceansix future paths Ltd. (“oceansix” or the “Company”), a leader in advanced recycling and manufacturing technological solutions with a presence on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0), is pleased to announce that today it has entered into an asset purchase agreement (the “Agreement”) pursuant to which oceansix, through its subsidiary Oceansix S.L., has purchased the business of Original RePack Oy (“RePack”), a pioneer in reusable packaging systems with a decade of proven track record (the “Acquisition”). The Acquisition will allow the Company to reduce the reliance on single-use packaging in e-commerce deliveries, which is growing exponentially and reached an annual dispatch of 161 billion parcels in 2022.
Transaction Details
The total consideration for the Acquisition, based on the Company’s current share price, is valued by the parties at CDN $2,392,912. Pursuant to the Agreement, oceansix acquired the business of RePack in exchange for: (i) issuing 24,948,840 common shares in the capital of the Company (the “Shares”) to the shareholders of RePack; and (ii) a payment of USD $108,000 (the equivalent of CDN $147,517, based on current exchange rates) (the “Cash Payment”) on closing. 15,282,176 of the Shares were issued to the shareholders of RePack on closing of the Acquisition, with the balance to be issued to the shareholders of RePack in up to four subsequent installments, selected at the option of RePack.
The Acquisition is an arm’s length transaction. All Shares issued pursuant to the Agreement will be restricted from trading for four months and one day after issuance. The Agreement and Acquisition remain subject to the final approval of the TSX Venture Exchange (the “Exchange”). The price per share of Shares issued post-closing to shareholders of RePack will be subject to the Company’s share price at their time of issuance and calculated in accordance with the rules of the Exchange.
oceansix solidifies its commitment to reshaping the packaging Industry
“As a pioneering force in sustainable innovation and disruptive engineering, our recent acquisition of RePack marks a significant milestone in our journey towards a more sustainable future,” Elad Hameiri, CEO of oceansix, states. “Together with RePack we are entering the new era where packaging is used again and again.”
A Sustainable Satisfaction. Delivered.
RePack, now a central pillar in oceansix's mission, were the first ones who introduced reusable packaging to e-commerce. Jonne Hellgren, CEO of RePack, comments: "Together, we lead the movement against single-use packaging, by creating a true circular system. "Reduce. Reuse. RePack." becomes more than a slogan—it is our operational mantra."
A New Alliance for the End of Packaging Trash
This call to action reflects oceansix and RePack's shared vision for cleaner and more efficient deliveries. Jonne Hellgren emphasizes, "With oceansix, we will be able to make sustainability simple and engaging, creating a continuous loop of good. To make this happen it takes more than just a reusable product. It needs a truly circular, scalable system.”
Rebelling Against the Status Quo
The joint mission is unequivocally defined: to make reusable packaging very simple and convenient for retailers and their customers. “This collaboration is not a startup experiment, but a mature, credible, and scalable solution to revolutionize the e-commerce packaging industry,” emphasized Elad Hameiri, CEO of oceansix. RePack’s reusable packaging, backed by oceansix's 30 years of proven business execution and innovative proprietary technology, could finally become the standard solution to e-commerce packaging and put an end to single-use packaging trash. Hameiri accentuates: "It is not just a merger, it's a rebellion against the status quo.”
RePack Initiative: Keep Packing, Stop Trashing
Learn more about how oceansix and RePack are crafting the future of e-commerce by visiting our websites at oceansix.com and RePack.com. Connect with us on LinkedIn, Instagram to join our journey towards reducing packaging waste and creating more sustainable and engaging consumer experiences.
About oceansix
oceansix future paths Ltd. remains at the forefront of creating sustainable solutions that not only convert waste into valuable products but also advocate the principles of a circular economy. oceansix’s unwavering commitment to sustainability is intensified by its strategic alliance with RePack, magnifying its impact on global environmental challenges.
About RePack
RePack is more than just another reusable packaging supplier; they’re pioneers in revolutionising the way businesses approach packaging. Rather than simply selling packaging repeatedly, RePack is dedicated to establishing efficient reuse systems that eliminate the need for companies to constantly replenish their packaging supplies.
RePack’s mission is clear: to provide innovative reusable packaging solutions that not only shrink the environmental footprint of deliveries but also elevate the overall customer experience.
Disclaimer
This press release might include forward-looking statements based on current expectations and projections about future events. Generally, forward-looking statements and information may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, "plans", "believes", "seeks", "estimates" or "will". These are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ materially from those expressed or implied by such statements. In this press release, forward looking statements include statements regarding reducing the reliance on single-use packaging in e-commerce deliveries; the issuance of the balance of Shares; and receiving Exchange approval for closing the Acquisition. oceansix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Approval & Accuracy
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) assumes responsibility for the adequacy or accuracy of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515940303/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
